{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:03:02Z","timestamp":1790971382692,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, Pfizer"},{"name":"Conseil D\u00e9partemental 06","award":["2021-367"],"award-info":[{"award-number":["2021-367"]}]},{"name":"French Government"},{"DOI":"10.13039\/501100001665","name":"National Research Agency","doi-asserted-by":"crossref","award":["ANR-22-CE17-0046-01"],"award-info":[{"award-number":["ANR-22-CE17-0046-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"National Research Agency","doi-asserted-by":"crossref","award":["ANR-15-IDEX-01"],"award-info":[{"award-number":["ANR-15-IDEX-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"National Research Agency","doi-asserted-by":"crossref","award":["ANR-21-ESRE-0052"],"award-info":[{"award-number":["ANR-21-ESRE-0052"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"France G\u00e9nomique","award":["ANR-10-INBS-09-03"],"award-info":[{"award-number":["ANR-10-INBS-09-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast growth factor (FGF) signaling plays an important role in the pathogenesis of various respiratory diseases, including idiopathic pulmonary fibrosis (IPF). FGF ligands can exert both pro and anti-fibrotic effects, depending on the responding cell, the expression levels of FGF receptors (FGFR1-4), and the context of other signaling molecules such as Transforming growth factor \u03b2 (TGF-\u03b2). We evaluated here the effect of a modified version of a soluble FGFR3 decoy receptor (designated as \u201csFGFR3-Fc\u201d), which specifically sequesters profibrotic FGFR3 ligands, FGF1, FGF2, and FGF9 as a potential anti-fibrotic drug. We showed that FGF2 stimulated proliferation and expression of various fibrotic markers in human pulmonary fibroblasts from healthy donors and IPF patients. The sFGFR3-Fc was able to reduce these FGF2-mediated responses and also partially attenuate the profibrotic phenotype induced by TGF-\u03b2, including gel contraction. Furthermore, single-cell transcriptomic analyses revealed heterogeneity of IPF-derived fibroblasts for FGF2 response and confirmed the potential efficacy of sFGFR3-Fc in decreasing the expression of a subset of TGF-\u03b21 pathway genes. Finally, sFGFR3-Fc was shown to improve the progression of pulmonary fibrosis using both a preventive and therapeutic strategy, evaluated in the standard single bleomycin (BLM) instillation mouse model as well as in a more severe model of repeated BLM instillations, as evidenced by the reduction in ECM deposits, the recovery of body weight, and the restoration of lung function. Our data highlight the interplay between the TGF-\u03b2 and the FGF signaling pathways and demonstrates the potential of targeting profibrotic FGFR3 ligands as a therapeutic strategy for IPF.<\/jats:p>","DOI":"10.1093\/ajrcmb\/aanag012","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:30:33Z","timestamp":1770726633000},"page":"1251-1266","source":"Crossref","is-referenced-by-count":1,"title":["A FGFR3 decoy receptor attenuates lung fibroblast-to-myofibroblast transition and pulmonary fibrosis"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0441-9421","authenticated-orcid":false,"given":"C\u00e9lia","family":"Scribe","sequence":"first","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]},{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-8809","authenticated-orcid":false,"given":"Marine","family":"Gautier-Isola","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dellugat","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guyl\u00e8ne","family":"Rignol","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ghilain","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Marsault","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Etasse","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5582","authenticated-orcid":false,"given":"Marin","family":"Truchi","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Cadis","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mille","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Guardini","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1149-7716","authenticated-orcid":false,"given":"Georges","family":"Vassaux","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3687-212X","authenticated-orcid":false,"given":"Justin","family":"Delgado Cohen","sequence":"additional","affiliation":[{"name":"BioMedicine Design, Pfizer Research & Development , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2970-6122","authenticated-orcid":false,"given":"Javier G","family":"Pizarro","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H","family":"Cheng","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-0134","authenticated-orcid":false,"given":"Christian","family":"Czech","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-9182","authenticated-orcid":false,"given":"Bernard","family":"Mari","sequence":"additional","affiliation":[{"name":"UMR CNRS 7275 Inserm 1323, IPMC, IHU RespirERA, Universit\u00e9 C\u00f4te d\u2018Azur , Valbonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4051-8405","authenticated-orcid":false,"given":"Corentin","family":"Herbert","sequence":"additional","affiliation":[{"name":"Rare Disease, Worldwide Research and Development, Pfizer , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"2026082703534678500_aanag012-B1","doi-asserted-by":"publisher","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026082703534678500_aanag012-B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"key":"2026082703534678500_aanag012-B3","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082703534678500_aanag012-B4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082703534678500_aanag012-B6","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082703534678500_aanag012-B7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"key":"2026082703534678500_aanag012-B8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cytogfr.2021.09.002","article-title":"FGF\/FGFR signaling: from lung development to respiratory diseases","volume":"62","author":"Yang","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026082703534678500_aanag012-B9","doi-asserted-by":"publisher","first-page":"eaaz5506","DOI":"10.1126\/scitranslmed.aaz5506","article-title":"Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis","volume":"12","author":"Chakraborty","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026082703534678500_aanag012-B10","doi-asserted-by":"publisher","first-page":"L615","DOI":"10.1152\/ajplung.00185.2015","article-title":"FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro","volume":"310","author":"Joannes","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026082703534678500_aanag012-B11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1165\/rcmb.2021-0246OC","article-title":"FGF19 is downregulated in idiopathic pulmonary fibrosis and inhibits lung fibrosis in mice","volume":"67","author":"Justet","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1164\/rccm.202311-2021OC","article-title":"FGF21 signaling exerts anti-fibrotic properties during pulmonary fibrosis","volume":"211","author":"Ghanem","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082703534678500_aanag012-B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12931-015-0242-2","article-title":"Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis","volume":"16","author":"MacKenzie","year":"2015","journal-title":"Respir Res"},{"key":"2026082703534678500_aanag012-B14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.15252\/emmm.201506181","article-title":"Smooth muscle FGF\/TGF\u03b2 cross talk regulates atherosclerosis progression","volume":"8","author":"Chen","year":"2016","journal-title":"EMBO Mol Med"},{"key":"2026082703534678500_aanag012-B15","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/s41598-022-20036-7","article-title":"FGF-2 enhances fibrogenetic changes in TGF-\u03b22 treated human conjunctival fibroblasts","volume":"12","author":"Tsugeno","year":"2022","journal-title":"Sci Rep"},{"key":"2026082703534678500_aanag012-B16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/jcmm.14793","article-title":"A new FGFR inhibitor disrupts the TGF-\u03b21-induced fibrotic process","volume":"24","author":"Kim","year":"2020","journal-title":"J Cellular Molecular Medi"},{"key":"2026082703534678500_aanag012-B17","doi-asserted-by":"publisher","first-page":"43000","DOI":"10.1074\/jbc.M510441200","article-title":"Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-\u03b21-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK","volume":"280","author":"Khalil","year":"2005","journal-title":"J Biol Chem"},{"key":"2026082703534678500_aanag012-B18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1046\/j.1523-1755.2001.059002579.x","article-title":"TGF-\u03b21 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2)","volume":"59","author":"Strutz","year":"2001","journal-title":"Kidney Int"},{"key":"2026082703534678500_aanag012-B19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1248\/bpb.35.731","article-title":"Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates Bleomycin-Induced pulmonary fibrosis in mice","volume":"35","author":"Yu","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"2026082703534678500_aanag012-B20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1165\/rcmb.2019-0090OC","article-title":"Blockade of Pan-Fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis","volume":"63","author":"Morizumi","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B21","doi-asserted-by":"publisher","first-page":"e10568","DOI":"10.1002\/jbm4.10568","article-title":"Longitudinal imaging of the skull base synchondroses demonstrate prevention of a premature ossification after recifercept treatment in mouse model of achondroplasia","volume":"6","author":"Rignol","year":"2022","journal-title":"JBMR Plus"},{"key":"2026082703534678500_aanag012-B22","doi-asserted-by":"publisher","first-page":"e0244368","DOI":"10.1371\/journal.pone.0244368","article-title":"In vitro and in vivo characterization of recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia","volume":"15","author":"Gon\u00e7alves","year":"2020","journal-title":"Plos One"},{"key":"2026082703534678500_aanag012-B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.str.2011.10.022","article-title":"The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition","volume":"20","author":"Kalinina","year":"2012","journal-title":"Structure"},{"key":"2026082703534678500_aanag012-B24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling","volume":"3","author":"Tomasek","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026082703534678500_aanag012-B25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1126\/science.aam8999","article-title":"SPLiT-seq reveals cell types and lineages in the developing brain and spinal cord","volume":"360","author":"Rosenberg","year":"2018","journal-title":"Science"},{"key":"2026082703534678500_aanag012-B26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","article-title":"An official American Thoracic Society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis","volume":"56","author":"Jenkins","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.yexmp.2006.12.003","article-title":"Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis","volume":"83","author":"Higashiyama","year":"2007","journal-title":"Exp Mol Pathol"},{"key":"2026082703534678500_aanag012-B28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12931-020-01582-y","article-title":"Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan","volume":"21","author":"Ikeda","year":"2020","journal-title":"Respir Res"},{"key":"2026082703534678500_aanag012-B29","doi-asserted-by":"publisher","first-page":"L442","DOI":"10.1152\/ajplung.00026.2010","article-title":"Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis","volume":"299","author":"Degryse","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026082703534678500_aanag012-B30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1165\/rcmb.2020-0542MA","article-title":"Persistent, progressive pulmonary fibrosis and epithelial remodeling in mice","volume":"64","author":"Redente","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41556-020-0542-8","article-title":"Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis","volume":"22","author":"Kobayashi","year":"2020","journal-title":"Nat Cell Biol"},{"key":"2026082703534678500_aanag012-B32","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","article-title":"Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis","volume":"11","author":"Strunz","year":"2020","journal-title":"Nat Commun"},{"key":"2026082703534678500_aanag012-B33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1369\/0022155413497366","article-title":"Expression of fibroblast growth factor 9 in normal human lung and idiopathic pulmonary fibrosis","volume":"61","author":"Coffey","year":"2013","journal-title":"J Histochem Cytochem"},{"key":"2026082703534678500_aanag012-B34","doi-asserted-by":"publisher","first-page":"27650","DOI":"10.1074\/jbc.M000893200","article-title":"Transforming growth factor-\u03b21-induced activation of the ERK pathway\/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor","volume":"275","author":"Finlay","year":"2000","journal-title":"J Biol Chem"},{"key":"2026082703534678500_aanag012-B35","doi-asserted-by":"publisher","first-page":"e13794","DOI":"10.14814\/phy2.13794","article-title":"TGF beta inhibits HGF, FGF7, and FGF10 expression in normal and IPF lung fibroblasts","volume":"6","author":"Correll","year":"2018","journal-title":"Physiol Rep"},{"key":"2026082703534678500_aanag012-B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/path.5106","article-title":"Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation","volume":"246","author":"Koo","year":"2018","journal-title":"J Pathol"},{"key":"2026082703534678500_aanag012-B37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1165\/rcmb.2020-0156ED","article-title":"Fibroblast growth factor inhibitors in lung fibrosis: friends or foes?","volume":"63","author":"Guzy","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11684-019-0717-5","article-title":"Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors","volume":"14","author":"Chu","year":"2020","journal-title":"Front Med"},{"key":"2026082703534678500_aanag012-B39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00018-022-04327-w","article-title":"Fgfr2b signaling is essential for the maintenance of the alveolar epithelial type 2 lineage during lung homeostasis in mice","volume":"79","author":"Ahmadvand","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"2026082703534678500_aanag012-B40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.stemcr.2019.04.003","article-title":"FGF10-FGFR2B signaling generates basal cells and drives alveolar epithelial regeneration by bronchial epithelial stem cells after lung injury","volume":"12","author":"Yuan","year":"2019","journal-title":"Stem Cell Rep"},{"key":"2026082703534678500_aanag012-B41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1165\/rcmb.2019-0079OC","article-title":"FGFR2 is required for AEC2 homeostasis and survival after bleomycin-induced lung injury","volume":"62","author":"Dorry","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B42","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.7150\/thno.93519","article-title":"Highlighting fibroblast plasticity in lung fibrosis: the WI-38 cell line as a model for investigating the myofibroblast and lipofibroblast switch","volume":"14","author":"V\u00e1squez-Pacheco","year":"2024","journal-title":"Theranostics"},{"key":"2026082703534678500_aanag012-B43","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1007\/s00018-017-2649-z","article-title":"The role of periostin in lung fibrosis and airway remodeling","volume":"74","author":"O\u2019Dwyer","year":"2017","journal-title":"Cell Mol Life Sci CMLS"},{"key":"2026082703534678500_aanag012-B44","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1378\/chest.13-2688","article-title":"Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis","volume":"146","author":"Jaffar","year":"2014","journal-title":"Chest"},{"key":"2026082703534678500_aanag012-B45","doi-asserted-by":"publisher","first-page":"e124529","DOI":"10.1172\/jci.insight.124529","article-title":"Fibulin-1c regulates transforming growth factor\u2013\u03b2 activation in pulmonary tissue fibrosis","volume":"5","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"2026082703534678500_aanag012-B46","doi-asserted-by":"publisher","first-page":"2300482","DOI":"10.1183\/13993003.00482-2023","article-title":"Evidence for a lipofibroblast-to-Cthrc1 + myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice","volume":"65","author":"Lingampally","year":"2025","journal-title":"Eur Respir J"},{"key":"2026082703534678500_aanag012-B47","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1172\/JCI125890","article-title":"Stromal integrin \u03b111 regulates PDGFR\u03b2 signaling and promotes breast cancer progression","volume":"129","author":"Primac","year":"2019","journal-title":"J Clin Invest"},{"key":"2026082703534678500_aanag012-B48","doi-asserted-by":"publisher","first-page":"eaba1972","DOI":"10.1126\/sciadv.aba1972","article-title":"Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis","volume":"6","author":"Habermann","year":"2020","journal-title":"Sci Adv"},{"key":"2026082703534678500_aanag012-B49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/febs.15570","article-title":"A guide to assessing cellular senescence in vitro and in vivo","volume":"288","author":"Gonz\u00e1lez-Gualda","year":"2021","journal-title":"Febs J"},{"key":"2026082703534678500_aanag012-B50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41586-024-07660-1","article-title":"Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis","volume":"631","author":"Tsukui","year":"2024","journal-title":"Nature"},{"key":"2026082703534678500_aanag012-B51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.stem.2016.10.004","article-title":"Two-Way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis","volume":"20","author":"El Agha","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2026082703534678500_aanag012-B52","doi-asserted-by":"publisher","first-page":"eadh0908","DOI":"10.1126\/scitranslmed.adh0908","article-title":"Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis","volume":"15","author":"Lang","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026082703534678500_aanag012-B53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/path.4825","article-title":"Fibroblast growth factors and pulmonary fibrosis: it\u2019s more complex than it sounds","volume":"241","author":"Kim","year":"2017","journal-title":"J Pathol"},{"key":"2026082703534678500_aanag012-B54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mam.2018.08.004","article-title":"Developmental pathways in the pathogenesis of lung fibrosis","volume":"65","author":"Chanda","year":"2019","journal-title":"Mol Aspects Med"},{"key":"2026082703534678500_aanag012-B55","doi-asserted-by":"publisher","first-page":"918771","DOI":"10.3389\/fphar.2022.918771","article-title":"Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis","volume":"13","author":"Ma","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026082703534678500_aanag012-B56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00441-016-2426-6","article-title":"Periostin as a multifunctional modulator of the wound \u00adhealing response","volume":"365","author":"Walker","year":"2016","journal-title":"Cell Tissue Res"},{"key":"2026082703534678500_aanag012-B57","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2025-0030OC","article-title":"Matrix softness induces an afibrogenic lipofibroblast phenotype in fibroblasts from IPF patients","author":"Berhan","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026082703534678500_aanag012-B58","doi-asserted-by":"crossref","first-page":"10364","DOI":"10.1074\/jbc.M117.791764","article-title":"Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling","volume":"292","author":"Guzy","year":"2017","journal-title":"J Biol Chem"},{"key":"2026082703534678500_aanag012-B59","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"2026082703534678500_aanag012-B60","doi-asserted-by":"publisher","first-page":"174510","DOI":"10.1016\/j.ejphar.2021.174510","article-title":"TGF-\u03b2-induced fibrosis: a review on the underlying mechanism and potential therapeutic strategies","volume":"911","author":"Ong","year":"2021","journal-title":"Eur J Pharmacol"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/advance-article-pdf\/doi\/10.1093\/ajrcmb\/aanag012\/67063463\/aanag012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/74\/9\/1251\/67063463\/aanag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/74\/9\/1251\/67063463\/aanag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:53:53Z","timestamp":1787817233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/74\/9\/1251\/8494341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,2,21]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrcmb\/aanag012","relation":{},"ISSN":["1535-4989"],"issn-type":[{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,2,21]]}}}